Patent 12134654 was granted and assigned to Marengo Therapeutics on November, 2024 by the United States Patent and Trademark Office.
Multispecific molecules targeting tumor associated macrophages (TAMs) or myeloid derived suppressor cells (MDSCs) and methods of using the same, are disclosed.